MicroRNA-338-3p suppresses metastasis of lung cancer cells by targeting the EMT regulator Sox4

American Journal of Cancer Research

Volumn 6, Issue 2, 2016, Pages 127-140

  Li, Yang ^a   Chen, Peirui ^a   Zu, Lingling ^a   Liu, Bin ^a   Wang, Min ^a   Zhou, Qinghua ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Metastasis; MiR 338 3p; NSCLC; Sox4

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; MICRORNA; PROTEIN MIR 338 3P; REGULATOR PROTEIN; TRANSCRIPTION FACTOR SOX4; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

3' UNTRANSLATED REGION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG PROTEIN BINDING; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER CELL LINE; MALE; METASTASIS INHIBITION; MIDDLE AGED; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REVIEW; UPREGULATION;

EID: 84981765087     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Travis WD. Pathology of lung cancer. Clin Chest Med 2002; 23: 65-81, viii.
2. Chen T, Xu C, Chen J, Ding C, Xu Z, Li C and Zhao J. MicroRNA-203 inhibits cellular proliferation and invasion by targeting Bmi1 in non-small cell lung cancer. Oncol Lett 2015; 9: 2639-2646.
3. Zhong C, Ding S, Xu Y and Huang H. MicroRNA-222 promotes human non-small cell lung cancer H460 growth by targeting p27. Int J Clin Exp Med 2015; 8: 5534-5540.
4. Zhu D, Chen H, Yang X, Chen W, Wang L, Xu J and Yu L. Decreased microRNA-224 and its clinical significance in non-small cell lung cancer patients. Diagn Pathol 2014; 9: 198.
5. Luo W, Huang B, Li Z, Li H, Sun L, Zhang Q, Qiu X and Wang E. MicroRNA-449a is downregulated in non-small cell lung cancer and inhibits migration and invasion by targeting c-Met. PLoS One 2013; 8: e64759.
6. Lin Y, Wu J, Chen H, Mao Y, Liu Y, Mao Q, Yang K, Zheng X and Xie L. Cyclin-dependent kinase 4 is a novel target in micoRNA-195-mediated cell cycle arrest in bladder cancer cells. FEBS Lett 2012; 586: 442-447.
7. Wang J, Gu Z, Ni P, Qiao Y, Chen C, Liu X, Lin J, Chen N and Fan Q. NF-kappaB P50/P65 hetero-dimer mediates differential regulation of CD166/ALCAM expression via interaction with micoRNA-9 after serum deprivation, providing evidence for a novel negative auto-regulatory loop. Nucleic Acids Res 2011; 39: 6440-6455.
8. Xiao H, Zeng J, Li H, Chen K, Yu G, Hu J, Tang K, Zhou H, Huang Q, Li A, Li Y, Ye Z, Wang J and Xu H. MiR-1 downregulation correlates with poor survival in clear cell renal cell carcinoma where it interferes with cell cycle regulation and metastasis. Oncotarget 2015; 6: 13201-13215.
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
10. Kos A, Olde Loohuis NF, Wieczorek ML, Glennon JC, Martens GJ, Kolk SM and Aschrafi A. A potential regulatory role for intronic microRNA-338-3p for its host gene encoding apoptosis-associated tyrosine kinase. PLoS One 2012; 7: e31022.
11. Saba R, Goodman CD, Huzarewich RL, Robertson C and Booth SA. A miRNA signature of prion induced neurodegeneration. PLoS One 2008; 3: e3652.
12. Huang N, Wu Z, Lin L, Zhou M, Wang L, Ma H, Xia J, Bin J, Liao Y and Liao W. MiR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling. Oncotarget 2015; 6: 15222-15234.
13. Sun K, Su G, Deng H, Dong J, Lei S and Li G. Relationship between miRNA-338-3p expression and progression and prognosis of human colorectal carcinoma. Chin Med J (Engl) 2014; 127: 1884-1890.
14. Sun J, Feng X, Gao S and Xiao Z. microRNA-338-3p functions as a tumor suppressor in human nonsmallcell lung carcinoma and targets Ras-related protein 14. Mol Med Rep 2015; 11: 1400-1406.
15. Fu X, Tan D, Hou Z, Hu Z, Liu G, Ouyang Y and Liu F. The effect of miR-338-3p on HBx deletion-mutant (HBx-d382) mediated liver-cell proliferation through CyclinD1 regulation. PLoS One 2012; 7: e43204.
16. Xu H, Zhao L, Fang Q, Sun J, Zhang S, Zhan C, Liu S and Zhang Y. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1alpha. PLoS One 2014; 9: e115565.
17. Wang G, Sun Y, He Y, Ji C, Hu B and Sun Y. MicroRNA-338-3p inhibits cell proliferation in hepatocellular carcinoma by target forkhead box P4 (FOXP4). Int J Clin Exp Pathol 2015; 8: 337-344.
18. Schepers GE, Teasdale RD and Koopman P. Twenty pairs of sox: extent, homology, and nomenclature of the mouse and human sox transcription factor gene families. Dev Cell 2002; 3: 167-170.
19. Wegner M. From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res 1999; 27: 1409-1420.
20. Cheung M, Abu-Elmagd M, Clevers H and Scotting PJ. Roles of Sox4 in central nervous system development. Brain Res Mol Brain Res 2000; 79: 180-191.
21. Kang M, Li Y, Liu W, Wang R, Tang A, Hao H, Liu Z and Ou H. miR-129-2 suppresses proliferation and migration of esophageal carcinoma cells through downregulation of SOX4 expression. Int J Mol Med 2013; 32: 51-58.
22. Wang L, Li Y, Yang X, Yuan H, Li X, Qi M, Chang YW, Wang C, Fu W, Yang M, Zhang J and Han B. ERG-SOX4 interaction promotes epithelial-mesenchymal transition in prostate cancer cells. Prostate 2014; 74: 647-658.
23. Huang HY, Cheng YY, Liao WC, Tien YW, Yang CH, Hsu SM and Huang PH. SOX4 transcriptionally regulates multiple SEMA3/plexin family members and promotes tumor growth in pancreatic cancer. PLoS One 2012; 7: e48637.
24. Zhou Q, Wang Y, Che G, Zhu W, Chen X, Chen X and Sun Z. [Establishment and their biological characteristics of clonal cell subpopulations (NL9980 and L9981) from a human lung large cell carcinoma cell line (WCQH-9801)]. Zhongguo Fei Ai Za Zhi 2003; 6: 464-468.
25. Li CY, Tan L, Zhang GJ, Li P, Tong C, Fan J and Zhu YS. Transcriptional regulation of urokinase receptor in high-(95D) and low-metastatic (95C) human lung cancer cells. Acta Biochim Biophys Sin (Shanghai) 2004; 36: 405-411.
26. Liu H, Li Y, Li Y, Liu B, Wu H, Wang J, Wang Y, Wang M, Tang SC, Zhou Q and Chen J. Cloning and functional analysis of FLJ20420: a novel transcription factor for the BAG-1 promoter. PLoS One 2012; 7: e34832.
27. Koumangoye RB, Andl T, Taubenslag KJ, Zilberman ST, Taylor CJ, Loomans HA and Andl CD. SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells. Mol Cancer 2015; 14: 24.
28. Tiwari N, Tiwari VK, Waldmeier L, Balwierz PJ, Arnold P, Pachkov M, Meyer-Schaller N, Schubeler D, van Nimwegen E and Christofori G. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell 2013; 23: 768-783.
29. You J, Li Y, Fang N, Liu B, Zu L, Chang R, Li X and Zhou Q. MiR-132 suppresses the migration and invasion of lung cancer cells via targeting the EMT regulator ZEB2. PLoS One 2014; 9: e91827.
30. Liu B, Wu X, Liu B, Wang C, Liu Y, Zhou Q and Xu K. MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN. Biochim Biophys Acta 2012; 1822: 1692-1704.
31. Li P, Chen X, Su L, Li C, Zhi Q, Yu B, Sheng H, Wang J, Feng R, Cai Q, Li J, Yu Y, Yan M, Liu B and Zhu Z. Epigenetic silencing of miR-338-3p contributes to tumorigenicity in gastric cancer by targeting SSX2IP. PLoS One 2013; 8: e66782.
32. Sun K, Deng HJ, Lei ST, Dong JQ and Li GX. miRNA-338-3p suppresses cell growth of human colorectal carcinoma by targeting smoothened. World J Gastroenterol 2013; 19: 2197-2207.
33. Vervoort SJ, Lourenco AR, van Boxtel R and Coffer PJ. SOX4 mediates TGF-beta-induced expression of mesenchymal markers during mammary cell epithelial to mesenchymal transition. PLoS One 2013; 8: e53238.
34. Shiota M, Itsumi M, Takeuchi A, Imada K, Yokomizo A, Kuruma H, Inokuchi J, Tatsugami K, Uchiumi T, Oda Y and Naito S. Crosstalk between EMT and castration resistance mediated by Twist1/AR signaling in prostate cancer. Endocr Relat Cancer 2015; 22: 889-900.
35. Mitra A, Mishra L and Li S. EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget 2015; 6: 10697-10711.
36. Sakamoto S and Ichikawa T. [Mechanism of prostate cancer invasion and metastasis]. Nihon Rinsho 2014; 72: 2086-2089.
37. Zhang J, Liang Q, Lei Y, Yao M, Li L, Gao X, Feng J, Zhang Y, Gao H, Liu DX, Lu J and Huang B. SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression. Cancer Res 2012; 72: 4597-4608.
38. Davis FM, Stewart TA, Thompson EW and Monteith GR. Targeting EMT in cancer: opportunities for pharmacological intervention. Trends Pharmacol Sci 2014; 35: 479-488.
39. Kaufhold S and Bonavida B. Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention. J Exp Clin Cancer Res 2014; 33: 62.